Loading...
•
Sep 30, 2020
10X Genomics Q3 2020 Earnings Report
Reported a revenue increase of 17% year-over-year, completed acquisitions of ReadCoor and CartaNA, and completed a follow-on public offering.
Key Takeaways
10x Genomics reported a strong third quarter with a 17% increase in revenue compared to the same period last year. The company completed acquisitions of ReadCoor and CartaNA, expanding its capabilities in In Situ analysis. A follow-on public offering generated approximately $482.2 million in net proceeds.
Revenue was $71.8 million, a 17% increase year-over-year.
Completed acquisitions of ReadCoor and CartaNA, advancing into In Situ analysis.
Gross margin was 80%, up from 75% in the prior year period.
Completed a follow-on public offering, resulting in approximately $482.2 million in net proceeds.
Forward Guidance
10x Genomics has withdrawn its annual revenue guidance for 2020 due to the evolving environment and continued uncertainties from the impact of COVID-19.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...